渤健Biogen (BIIB) 2017年年度报告「NASDAQ」.pdf

1、PIONEERING THE FUTUREOF NEUROSCIENCE2017 ANNUAL REPORTYEARS1|2017 Biogen Annual Report1|2017 Biogen Annual ReportAbout the CoverLeft:Ankur is Senior Associate Scientist,Neurology Research at Biogen Right:Erin is Associate Director,Pharmaceutical Development,Pharmaceutical Operations&Technology(PO&T)

2、and Albert is Principal Scientist,Pharmaceutical Development,PO&T at Biogen About the Graphic Artwork The artwork highlighted in the report was submitted by Biogens R&D team as part of our annual RAD(Research and Development)Art contest.Each image reflects work underway in the lab every day.2017 Bio

3、gen Annual Report|2FINANCIAL PERFORMANCE$6,932$7.81$8.96$2,084$9,703$12.37$13.83$2,279$10,764$15.34$17.01$2,223$11,499$16.93$20.22$2,706$12,274$11.921$21.81$2,4842REVENUES$in millionsGAAP DILUTED EPSNON-GAAP DILUTED EPS*FREE CASHFLOW*$in millions201320142015201620172013201420152016201720132014201520

4、162017201320142015201620171“GAAP diluted EPS”for 2017 reflects the impact of The Tax Cuts and Jobs Act of 2017 and higher costs associated with our external business development activities,including our agreements with Bristol-Myers Squibb Company,Ionis Pharmaceuticals Inc.,Neurimmune Subone AGand A

5、lkermes Pharma Ireland Limited,a subsidiary of Alkermes plc.2“Free Cash Flow*”for 2017 reflects an increase in capital expenditures related to the construction of our large-scale biologics manufacturing facility in Solothurn,Switzerland.*“Non-GAAP diluted EPS”and“Free Cash Flow”are Non-GAAP financia

6、l measures.A reconciliation of GAAP to Non-GAAP diluted EPS and Free Cash Flow amounts is set forth on pages 18-20 of this Annual Report.GAAP DILUTED EPSREVENUES$in millionsNON-GAAP DILUTED EPS*FREE CASHFLOW*$in millionsFINANCIAL PERFORMANCE 3|2017 Biogen Annual Report MICHEL VOUNATSOSCHIEF EXECUTIV